No effects of lifelong creatine supplementation on sarcopenia in senescence-accelerated mice (SAMP8).
Oral creatine supplementation can acutely ameliorate skeletal muscle function in older humans, but its value in the prevention of sarcopenia remains unknown. We evaluated the effects of lifelong creatine supplementation on muscle mass and morphology, contractility, and metabolic properties in a mouse model of muscle senescence. Male senescence-accelerated mice (SAMP8) were fed control or creatine-supplemented (2% of food intake) diet from the age of 10 to 60 wk. Soleus and extensor digitorum longus muscles were tested for in vitro contractile properties, creatine content, and morphology at weeks 25 and 60. Both muscle types showed reduced phosphocreatine content at week 60 that could not be prevented by creatine. Accordingly, age-associated decline in muscle mass and contractility was not influenced by treatment. Aged soleus muscles had fewer and smaller fast-twitch glycolytic fibers irrespective of treatment received. It is concluded that lifelong creatine supplementation is no effective strategy to prevent sarcopenia in senescence-accelerated mice.
Derave
Wim
W
Exercise Physiology and Biomechanics Laboratory, Faculty of Kinesiology and Rehabilitation Sciences, Tervuursevest 101, B-3001 Leuven, Belgium. wim.derave@faber.kuleuven.be
Eijnde
Bert O
BO
Ramaekers
Monique
M
Hespel
Peter
P
D000375:Aging / Q000235:genetics / Q000473:pathology*; D000818:Animals; D003401:Creatine / Q000378:metabolism / Q000627:therapeutic use*; D019587:Dietary Supplements; D004734:Energy Metabolism / Q000502:physiology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009119:Muscle Contraction / Q000502:physiology; D018485:Muscle Fibers, Skeletal / Q000378:metabolism / Q000473:pathology*; D018482:Muscle, Skeletal / Q000378:metabolism / Q000473:pathology*; D009133:Muscular Atrophy / Q000378:metabolism / Q000517:prevention & control*; D009929:Organ Size; D016896:Treatment Outcome
D003401:Creatine